Thirty-Day Readmission Rates After Takotsubo Syndrome With or Without Malignancy: A Nationwide Readmissions Database Analysis

Sun-Joo Jang (✉ drjalive@gmail.com)

Weill Cornell Medical College: Weill Cornell Medicine <https://orcid.org/0000-0002-4311-4855>

Ilhwan Yeo

NewYork-Presbyterian Queens

Chanel Jonas

Weill Cornell Medical College: Weill Cornell Medicine

Parag Goyal

Weill Cornell Medical College: Weill Cornell Medicine

Jim W. Cheung

Weill Cornell Medical College: Weill Cornell Medicine

Dmitriy N. Feldman

Weill Cornell Medical College: Weill Cornell Medicine

S. Andrew McCullough

Weill Cornell Medical College: Weill Cornell Medicine

Udhay Krishnan

Weill Cornell Medical College: Weill Cornell Medicine

David L. Narotsky

Weill Cornell Medical College: Weill Cornell Medicine

Harsimran S. Singh

Weill Cornell Medical College: Weill Cornell Medicine

Robert M. Minutello

Weill Cornell Medical College: Weill Cornell Medicine

Geoffrey Bergman

Weill Cornell Medical College: Weill Cornell Medicine

S. Chiu Wong

Weill Cornell Medical College: Weill Cornell Medicine

Luke K. Kim

Weill Cornell Medical College: Weill Cornell Medicine

Keywords: Takotsubo syndrome, Malignancy, Readmission, Cardio-oncology

Posted Date: October 9th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-87272/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Journal of Clinical Medicine on August 20th, 2021. See the published version at <https://doi.org/10.3390/jcm10163701>.

Abstract

Background: Association of malignancy with readmission after TTS hospitalization has not been fully described. We sought to examine the rates, cause and cost of 30-day readmissions and 30-day all-cause mortality of Takotsubo syndrome (TTS) patients with or without malignancy.

Methods: The Nationwide Readmissions Databases from 2010 to 2014 were queried to identify and compare baseline characteristics and outcomes of patients hospitalized for TTS with and without malignancy.

Results: We identified 61,588 index hospitalizations for TTS. TTS patients with malignancy were older (70.6 ± 0.2 vs. 66.1 ± 0.1 , $p < 0.001$), and the overall burden of comorbidities was higher than in those without malignancy. TTS patients with malignancy had significantly higher 30-day readmission rates than those without malignancy (15.9% vs. 11.0%; odds ratio [OR], 1.35; 95% confidence interval [CI], 1.18 - 1.56). Majority (75.5%) of the etiologies for readmissions were non-cardiac, with infection being most common (20.1%). The 30-day readmission rate due to the recurrent TTS was similar in both groups (0.4% and 0.5%, respectively; $p = 0.47$). Importantly, 30-day all-cause mortality was higher in TTS with vs. without malignancy (4.8% vs 2.5%; OR, 1.62; 95% CI, 1.25 - 2.10). The total costs (index admission + readmission) were higher by 25% ($p < 0.001$) in TTS patients with malignancy vs. without malignancy.

Conclusions: In patients hospitalized with TTS, the presence of malignancy was associated with increased risk of 30-day readmission, mostly attributable to non-cardiac etiologies. Importantly, the 30-day all-cause mortality and cost were also significantly higher. These findings highlight the importance of optimization of treatment and follow up in patients with malignancy after hospitalizations for TTS.

Introduction

Takotsubo syndrome (TTS), also known as stress-induced cardiomyopathy can mimic acute coronary syndrome (ACS) and is an increasingly recognized cause of heart failure [1, 2]. There are multiple theories as to the pathophysiology of TTS, though the exact mechanisms of remain uncertain [3]. The association between malignancy/chemotherapy and TTS has been reported in multiple studies [4-6]. Cancer patients who undergo systemic chemotherapy and/or radiation therapy often develop endothelial dysfunction in their epicardial and microvascular coronary vasculatures, which may play an important role in the high frequency of TTS observed in this cohort.

A recent study demonstrated a high prevalence of malignancy among TTS patients with an increased long-term mortality in TTS patients with concomitant malignancy [4, 5]. Although TTS has been shown to be associated with frequent (12%) 30-day readmission, the clinical impact of readmission in TTS patients with malignancy and its associated economic burden on the US healthcare system is less evident [6, 7]. Using the Nationwide Readmission Database (NRD), we sought to delineate the incidence, etiology, clinical impact and costs of 30-day readmission in TTS patients with versus without malignancy.

Methods

Data Source

Data were obtained from the Agency for Healthcare Research and Quality, which administers the Healthcare Cost and Utilization Project (HCUP) [8, 9]. We used the NRD from 2010 to 2014. The NRD is a large, administrative database constructed using discharge data from HCUP State Inpatient Databases. It has verified patient linkage numbers used to track the patients across hospitals within a state during a given year. The NRD is designed to support national readmission analyses and is a publicly available national representative healthcare database. From 2010 to 2014, the NRD contained deidentified information for a total of 70,501,787 index hospitalizations from 1,715 – 2,048 hospitals in 18 – 20 states, representing a national estimate of 181,545,077 discharges. Each patient record in the NRD contains information on the patient's diagnoses and procedures performed during the hospitalization based on International Classification of Diseases, Ninth Revision-Clinical Modification (ICD-9-CM) codes and Clinical Classification Software (CCS) codes that groups multiple ICD-9-CM codes for facilitated statistical analyses. We identified our study population, comorbidities, causes of readmissions, in-hospital outcomes using a combination of ICD-9-CM codes and CCS codes. Institutional Review Board approval and informed consent were not required for current study because all data collection was derived from a publicly open and deidentified administrative database.

Study Population and Variables

From 2010 to 2014, all index hospitalizations for TTS were selected using ICD-9-CM code 429.83. To ensure that cases were TTS and not from ACS, only those who underwent diagnostic coronary angiography (CCS 47) and no revascularization (Procedural CCS 44, 45 and ICD-9-CM procedure codes 36.06 and 36.07) were included in the analysis. Malignancy was identified by CCS code 11-45 [10]. Patients were categorized into 2 groups based on the presence or absence of malignancy.

Patient- and hospital-level variables were included as baseline characteristics. Patients with a concomitant diagnosis of cardiogenic shock and cardiac arrest were identified using ICD-9-CM codes 785.51 and 427.5, respectively. Concurrent use of intra-aortic balloon pump and percutaneous left ventricular assist devices were identified with ICD-9-CM procedure codes 37.61 and 37.68, respectively. Since NRD prohibits linking patients across years, patients whose index hospitalization was in December were excluded to allow for completeness of data on 30 days of follow-up after discharge as has been done in prior studies examining the NRD [11-13].

Study Outcomes

The primary outcome of interest was 30-day readmission rates after index hospitalization for TTS. For 30-day readmissions, only the first readmission within 30 days after discharge was included, and transfer to another hospital was not counted as a readmission. The primary cause of 30-day readmission was identified based on CCS code in the first diagnosis field of each readmission record and dichotomized into non-cardiac and cardiac causes [9]. Non-cardiac causes included respiratory, infectious, gastrointestinal,

neuropsychiatric/substance, stroke/transient ischemic attack, endocrine/metabolic, genitourinary, hematologic/oncologic, peripheral vascular disease, trauma, complication of medical procedure, and other non-cardiac causes. Cardiac causes included angina and chronic ischemic heart disease, heart failure, acute myocardial infarction, nonspecific chest pain, arrhythmia, and other cardiac causes. Furthermore, 30-day mortality rates along with breakdown of mortality rates during index hospitalization and during readmission were identified. Finally, total cumulative hospital charges and costs for index hospitalization and readmissions were examined according to the presence of malignancy.

Statistical Analyses

All statistical analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC) and R statistical software, version 3.5.1 (www.R-project.org) with its package “survey”. Discharge weight and stratum provided by NRD were used for all analyses and thus all reported numbers are weighted national estimates [14]. Domain analysis was used for accurate variance calculations for subgroup analyses [15]. All analyses accounted for NRD sampling design by including hospital-year fixed effects based on hospital identification number [8]. We compared baseline patient- and hospital-level characteristics with TTS stratified by the presence of malignancy. Categorical variables are presented as frequencies and analyzed by Rao-Scott chi-square test. Continuous variables are shown as mean or median and are tested by either Mann-Whitney-Wilcoxon test or survey-specific linear regression test. To evaluate the predictive value of malignancy and other covariates for primary and secondary outcomes, survey-specific univariate and multivariable generalized linear models were applied. Variables with $p < 0.1$ were included as initial covariates. Final parsimonious models were created by manual removal of each covariate based on Akaike information criterion while ensuring each removal did not result in $>10\%$ change in the measure of association for the primary predictor variable. Adjusted risks are presented in odds ratio (OR) together with 95% confidence interval (CI) and P value. The estimated cost for each hospitalization was calculated by the validated method of using cost-to-charge ratio provided by HCUP. Total cost was defined as the summation of the cost of readmission and the cost of the index admission. We examined the predictors of total cost by survey-specific multivariate linear regression test for log-transformed costs. All tests were two-sided with P value < 0.05 considered statistically significant.

Results

Baseline Characteristics

A total of 61,583 TTS admissions were included for the analysis with 7,542 patients (12.2%) with malignancy. The baseline patient-level and hospital-level characteristics according to the presence of malignancy are presented in Table 1. TTS patients with malignancy were more likely to be female and have smoking history, known coronary artery disease, congestive heart failure, chronic pulmonary disease, anemia, atrial fibrillation, coagulopathy, fluid/electrolyte disorders, pulmonary circulatory disease and valvular heart disease. TTS with concomitant cardiogenic shock was observed more frequently among those with malignancy. In addition, TTS patients with malignancy were admitted more frequently to teaching hospitals and discharged to facilities more often (such as skilled nursing facility, intermediate

care facility, and inpatient rehabilitation facility). There was no significant difference in the prevalence of psychiatric disorders, such as mood disorders, delirium/dementia, personality disorder between TTS patients with malignancy and those without malignancy.

Clinical Outcomes of TTS Patients With or Without Malignancy

In-hospital mortality in TTS patients with malignancy was significantly higher by ~2-fold when compared to those without malignancy (4.2% vs 2.1%, $p < 0.001$) (Table 2). There was more than 90% increase in the 30-day total mortality rates in the malignancy group, which was mostly driven by mortality during index-hospitalization. Multivariate analysis after adjusting for clinical and hospital characteristics demonstrated a 68% increase in the risk of index-hospitalization mortality (OR, 1.68; 95% CI, 1.29-2.17; $p < 0.01$) and a 62% increase in the risk of 30-day total mortality (OR, 1.62; 95% CI, 1.25-2.10; $p < 0.01$) in TTS patients with vs. without malignancy (Table 2, Supplementary Table I and II). There was no difference in 30-day readmission mortality between TTS patients with and without malignancy (0.6% vs. 0.4%, $p = 0.110$).

The 30-day readmission rate was significantly higher in TTS patients with malignancy than those without malignancy (15.9% vs 11.0%, $p < 0.001$) (Figure 1). After adjusting for clinical and hospital characteristics, there was a 33% increase in the risk of 30-day readmission in TTS patients with malignancy (OR, 1.33; 95% CI, 1.15-1.53; $p < 0.01$) (Table 3). Other significant predictors for 30-day readmission included a longer (>5 days) length of stay during index admission, chronic pulmonary disease, chronic kidney disease, anemia, atrial fibrillation, fluid/electrolyte disturbance, diabetes mellitus, low household income, and disposition to facility (Table 3).

Timing and Cause of Readmission

Figure 2 and Supplemental figure 1 demonstrate the timing of 30-day readmission stratified by presence of malignancy. The median time to readmission was longer in TTS patients with malignancy vs. without malignancy (12 days, interquartile range[IQR] 5-19 days vs. 9 days, IQR 4-17 days, respectively; $p=0.027$). 34% of TTS patients with malignancy and 43% without malignancy were readmitted within 7 days of discharge. 38% of TTS patients with malignancy and 33% without malignancy were readmitted after 14 days of discharge. Non-cardiac causes were more common causes of readmission for TTS patients with versus without malignancy (75.5% vs. 68.1%, $p < 0.001$) (Figure 2C, Supplementary Table III, IV, and V). Among cardiac causes, heart failure was the most prevalent in both TTS patients with and without malignancy (8.1% vs. 11.1%, $p = 0.002$), followed by arrhythmia (4.9% vs. 3.3%, $p = 0.006$, and angina (1.8% vs. 2.4%, $p = 0.234$). Among non-cardiac causes, infectious (20.1% vs. 12.0%, $p = <0.001$), respiratory (8.4% vs. 12.4%, $p < 0.001$), and gastrointestinal (7.8% vs. 9.5%, $p = 0.075$) causes were most prevalent in both groups. The 30-day readmission rate due to recurrent TTS was similarly low in both groups (0.4% vs. 0.5%, respectively; $p=0.47$).

Specific Cancer Type and Readmission

The prevalence of specific cancer types is shown in Figure 3A. The most frequent type of malignancy was breast cancer (27.9%), followed by gastrointestinal tract cancer (13.3%) and respiratory tract cancer

(12.2%). The 30-day readmission rate was the highest in patients with lymphoma (25.4%), head and neck cancer (24.9%), brain cancer (23.1%), urinary tract cancer (21.6%), and ovarian cancer (21.1%) (Figure 3B). TTS patients with skin (9.0%), uterus (10.0%), and prostate (10.4%) cancer had the lowest 30-day readmission rates compared to patients with other cancer.

Total Charges and Costs by the Presence of Malignancy and Predictors of Total Cost

Hospital charges and costs over 30 days after index hospitalization for TTS stratified by the presence of malignancy are shown in Supplementary Table VI. The median total charge (index hospitalization + readmissions) was \$10,201 higher in TTS patients with malignancy (\$50,936; IQR, \$29,819-\$97,989) than in those without malignancy (\$40,735; IQR, \$26,160-\$72,619) ($P<0.001$). The median total cost (index hospitalization + readmissions) was \$2,982 higher in TTS patients with malignancy (\$14,686; IQR, \$9,294-\$27,337) than in those without malignancy (\$11,704; IQR, \$8,065-\$19,630) ($P<0.001$). After multivariate adjustment, 30-day readmission was independently associated with a 22.3% increase in 30-day total cost (Table 4). Furthermore, the presence of malignancy was independently associated with a 1.3% increase in 30-day total cost. Other significant predictors for the increased total costs included length of stay >5 days, cardiogenic shock, and cardiac arrest.

Discussion

Using the 2010 to 2014 NRD to delineate 30-day clinical outcomes in patients hospitalized for TTS with or without malignancy, we identified several key findings. First, there was a high prevalence of malignancy (12.2%) among TTS patients. Second, 30-day readmission rates, all-cause mortality and total costs (index hospitalization + readmissions) were higher in TTS patients with malignancy compared to those without malignancy. Third, malignancy was independently associated with increased 30-day total charges and costs in patients hospitalized for TTS. The implications of these findings underscore the importance of optimal treatment strategy and close follow-up in patients with TTS and malignancy.

The 30-day readmission rate of TTS patients was 11.6%, similar to previous reports.[7, 16] Our study demonstrates that malignancy is associated with a significant risk of readmission after index hospitalization for TTS. It is noteworthy that median time to readmission is longer in TTS patients with malignancy (12 days) than in those without malignancy (9 days). A significant portion (34%) of TTS patients with malignancy were readmitted > 14 days after discharge. These findings highlight the need for optimal initial treatment strategy and vigilant attention beyond the initial 1-2 weeks follow-up visit, especially for in patients with malignancy. Our study demonstrates that heart failure is the most common cardiac cause of readmission, which is not surprising given the pathophysiology and clinical manifestation of TTS. Therefore, treatment strategies to optimize heart failure regimen and to minimize readmission after TTS are warranted [17]. Supportive discharge interventions, such as telephone-facilitated post-discharge support program, computer-based education sessions, or nurse-driven protocol-based management program, have shown to be effective in reducing the risk of early readmissions in heart failure population [18-22]. Furthermore, developing comprehensive programs for heart failure patients with patient-specific interventions based on risk profile and focus on both inpatient

and outpatient interventions with cross-site communications have shown to significantly reduce early readmissions [23]. However, efforts in reducing 30-day readmissions after TTS should also take into account the fact that majority of readmissions are due to non-cardiac causes. TTS is a complex disorder with variable clinical manifestation, and malignancy certainly presents an added layer to the complexity of TTS management. Infectious etiologies were the most frequent cause of readmission among TTS patients with malignancy in our study. Patients with malignancy are at increased risk of infections directly related to their cancer or due to their immunocompromised state from systemic chemotherapy [24]. Interdisciplinary approaches in coordinating outpatient programs focused on reducing readmissions by providing continuity of care from the inpatient to outpatient setting from both oncologists and cardiologists should be encouraged.

In the present study, the presence of malignancy is not associated with an increased risk of 30-day readmission from recurrent TTS. Reported recurrence rates of TTS are variable, ranging from 1% to 11.4% [25-27]. Analysis of the multicenter GEIST (German Italian Stress Cardiomyopathy) Registry data failed to identify any independent predictors of TTS recurrence [28]. Presence of malignancy has been shown to be associated with higher risk of TTS in numerous studies [29-31], and there are numerous reports of TTS associated with chemotherapy or immunotherapy [32-36]. It is plausible that interruption in chemotherapy after initial episode of TTS may play a role in explaining the lack of difference in TTS recurrence rate in those with malignancy. Post-TTS cancer treatment strategy, especially decisions regarding continuation of potentially life-saving chemotherapy, still remains a challenge. Future longer-term studies are necessary to detect whether TTS patients with malignancy are at risk of developing recurrent TTS.

Our study demonstrated that malignancy was associated with ~70% increase in in-hospital mortality risk during index hospitalization and ~60% increase in overall 30-day mortality risk in patients with TTS. A previous study from National Inpatient Sample 2007 to 2013 showed that solid cancer was associated with 3.4 times increase in in-hospital mortality among TTS patients [37]. Our analysis included all types of cancer (solid or hematologic cancer), which may explain slightly lower in-hospital mortality. Recent data from the International Takotsubo Registry have shown that long-term mortality was increased in TTS patients with malignancy while 30-day mortality was not significantly different in TTS patient with or without malignancy (7% vs 4%, $p = 0.17$). [29] Our study, however, demonstrates that total 30-day mortality rates in TTS patients with malignancy were significantly higher compared to those without malignancy. Further studies with a more extensive examination of out of hospital mortality are needed to examine this discrepancy.

Cost analysis of our study demonstrates that TTS is responsible for annual cost of ~\$148 million for index admission and 30-day readmission in the US (during the years from 2010 to 2014). Readmission within 30-days accounted for 22% increase in total costs among TTS patients. Furthermore, presence of malignancy increased the cumulative costs by 1.3% after index hospitalization for TTS. Although 30-day readmission is one of the most significant contributor of increased overall cost, presence of malignancy was an independent predictor of increased cost likely due to longer length of stay and higher frequency of cardiogenic shock. Our findings highlight the impact of TTS in patients with malignancy beyond just short-

and long-term mortality. TTS in patients with malignancy pose a significant economic burden on hospital resource and overall healthcare system, and our study supports the need for increased effort in reducing readmissions in this cohort.

This study has limitations that are largely due to its observational nature. First, the NRD is the administrative data, designed to estimate the national distribution of representative hospital characteristics, which is subject to coding bias or missing variables. Nevertheless, there have been numerous publications which validated the sampling design of NRD and utilization of NRD databases for risk-adjusted outcome evaluation [11, 16, 38]. Second, the NRD does not include detailed clinical characteristics, such as coronary anatomy, heart failure class, left ventricular ejection fraction, cardiac enzyme data or medications. Third, our analysis of the 30-day total mortality rate does not include out-of-hospital deaths, which may underestimate the overall incidence of mortality. Fourth, we used ICD-9-CM codes and CCS codes for defining clinical diagnoses and procedures, which may lead to misclassification bias. Finally, the result from the overall malignant population may not be generalizable to specific cancer types, stages, or treatment strategies. Nevertheless, the prevalence and 30-day readmission rates according to cancer types were addressed in this study.

Conclusions

In summary, malignancy is associated with an increased risk of 30-day readmission, all-cause mortality, and costs in TTS patients. The majority of hospital readmissions in TTS patients were caused by non-cardiac causes. Our findings highlight the importance of tailored and multidisciplinary patient-specific treatment approaches, along with careful coordination of outpatient follow-up care, particularly in TTS patients with malignancy.

Abbreviations

CCS: Clinical Classification Software

CI: Confidence Interval

HCUP: Healthcare Cost and Utilization Project

ICD-9-CM: International Classification of Diseases, Ninth Revision-Clinical Modification

NRD: Nationwide Readmissions Database

OR: Odds Ratio

SE: Standard Error

TTS: Takotsubo syndrome

Declarations

Ethical Approval and Consent to participate:

Institutional Review Board approval and informed consent were not required for current study because all data collection was derived from a publicly open and deidentified administrative database.

Consent for publication:

Not applicable

Availability of data and materials:

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests:

There is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Funding:

This research was supported by grants from the Michael Wolk Heart Foundation, the New York Cardiac Center, Inc, and the Weill Cornell Medical Center Alumni Council. The Michael Wolk Heart Foundation, the New York Cardiac Center, Inc, and the Weill Cornell Medical Center Alumni Council had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.

Authors' contributions:

SJ, IY and LK collected data from the Nationwide Readmission Database regarding the Takotsubo syndrome and cancer and performed statistical analysis. SJ, CJ and LK were a major contributor in writing the manuscript. PG, JC, DF, SM, UK, DN, HS, RM, GB contributed to clinical and statistical discussion on the results providing constructive suggestions. All authors read and approved the final manuscript."

Acknowledgement:

We thanks to members of Weill Cornell Cardiovascular Outcomes Research Group (CORG) for their stimulating discussion and supports.

References

1. Akashi YJ, Goldstein DS, Barbaro G, Ueyama T: **Takotsubo cardiomyopathy: a new form of acute, reversible heart failure.** *Circulation* 2008, **118**(25):2754-2762.

2. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W *et al*: **International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology.** *Eur Heart J* 2018, **39**(22):2032-2046.
3. Ghadri JR, Ruschitzka F, Luscher TF, Templin C: **Takotsubo cardiomyopathy: still much more to learn.** *Heart* 2014, **100**(22):1804-1812.
4. Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA *et al*: **Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy.** *N Engl J Med* 2015, **373**(10):929-938.
5. Ghadri JR, Kato K, Cammann VL, Gili S, Jurisic S, Di Vece D, Candreva A, Ding KJ, Micek J, Szawan KA *et al*: **Long-Term Prognosis of Patients With Takotsubo Syndrome.** *J Am Coll Cardiol* 2018, **72**(8):874-882.
6. Fingar K, Washington, R.: **Trends in Hospital Readmissions for Four High-Volume Conditions, 2009–2013.** HCUP Statistical Brief # 196. Available at: <http://www.hcup-us.ahrq.gov/reports/statbriefs/sb196-Readmissions-Trends-High-Volume-Conditions.pdf>. Published November 2015. Accessed September, 11, 2019.
7. Smilowitz NR, Hausvater A, Reynolds HR: **Hospital readmission following takotsubo syndrome.** *Eur Heart J Qual Care Clin Outcomes* 2019, **5**(2):114-120.
8. McIntyre E, Saliba A, McKenzie K: **Subjective wellbeing in the Indian general population: a validation study of the Personal Wellbeing Index.** *Qual Life Res* 2020, **29**(4):1073-1081.
9. Agency for Healthcare Research and Quality. **Overview of hospital stays in the United States, 2012.** Retrieved from <http://www.hcup-us.ahrq.gov/reports/statbriefs/sb180-Hospitalizations-United-States-2012.pdf>. 2014.
10. Rivera DR, Gallicchio L, Brown J, Liu B, Kyriacou DN, Shelburne N: **Trends in Adult Cancer-Related Emergency Department Utilization: An Analysis of Data From the Nationwide Emergency Department Sample.** *JAMA Oncol* 2017, **3**(10):e172450.
11. Kim LK, Yeo I, Cheung JW, Swaminathan RV, Wong SC, Charitakis K, Adejumo O, Chae J, Minutello RM, Bergman G *et al*: **Thirty-Day Readmission Rates, Timing, Causes, and Costs after ST-Segment-Elevation Myocardial Infarction in the United States: A National Readmission Database Analysis 2010-2014.** *J Am Heart Assoc* 2018, **7**(18):e009863.
12. Cheng EP, Liu CF, Yeo I, Markowitz SM, Thomas G, Ip JE, Kim LK, Lerman BB, Cheung JW: **Risk of Mortality Following Catheter Ablation of Atrial Fibrillation.** *J Am Coll Cardiol* 2019, **74**(18):2254-2264.
13. Cheung JW, Cheng EP, Wu X, Yeo I, Christos PJ, Kamel H, Markowitz SM, Liu CF, Thomas G, Ip JE *et al*: **Sex-based differences in outcomes, 30-day readmissions, and costs following catheter ablation of atrial fibrillation: the United States Nationwide Readmissions Database 2010-14.** *Eur Heart J* 2019, **40**(36):3035-3043.
14. Quality AfHRA: **Introduction to the HCUP Nationwide Readmissions Database (NRD).** Available at: https://www.hcupus.ahrq.gov/db/nation/nrd/Introduction_NRD_2010-2014.pdf. Accessed September 1, 2019.

15. Lohr SL: **Sampling: Design and Analysis.** *Pacific Grove, CA: Duxbury Press* 1999.
16. Shah M, Ram P, Lo KBU, Sirinvaravong N, Patel B, Tripathi B, Patil S, Figueredo VM: **Etiologies, predictors, and economic impact of readmission within 1 month among patients with takotsubo cardiomyopathy.** *Clin Cardiol* 2018, **41**(7):916-923.
17. Arora S, Patel P, Lahewala S, Patel N, Patel NJ, Thakore K, Amin A, Tripathi B, Kumar V, Shah H *et al*: **Etiologies, Trends, and Predictors of 30-Day Readmission in Patients With Heart Failure.** *Am J Cardiol* 2017, **119**(5):760-769.
18. Leppin AL, Gionfriddo MR, Kessler M, Brito JP, Mair FS, Gallacher K, Wang Z, Erwin PJ, Sylvester T, Boehmer K *et al*: **Preventing 30-day hospital readmissions: a systematic review and meta-analysis of randomized trials.** *JAMA Intern Med* 2014, **174**(7):1095-1107.
19. Stromberg A, Martensson J, Fridlund B, Levin LA, Karlsson JE, Dahlstrom U: **Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure: results from a prospective, randomised trial.** *Eur Heart J* 2003, **24**(11):1014-1023.
20. Wakefield BJ, Ward MM, Holman JE, Ray A, Scherubel M, Burns TL, Kienzle MG, Rosenthal GE: **Evaluation of home telehealth following hospitalization for heart failure: a randomized trial.** *Telemed J E Health* 2008, **14**(8):753-761.
21. Linne AB, Liedholm H: **Effects of an interactive CD-program on 6 months readmission rate in patients with heart failure - a randomised, controlled trial [NCT00311194].** *BMC Cardiovasc Disord* 2006, **6**:30.
22. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM: **A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure.** *N Engl J Med* 1995, **333**(18):1190-1195.
23. Coleman EA, Parry C, Chalmers S, Min SJ: **The care transitions intervention: results of a randomized controlled trial.** *Arch Intern Med* 2006, **166**(17):1822-1828.
24. Vento S, Cainelli F: **Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment.** *Lancet Oncol* 2003, **4**(10):595-604.
25. Elesber AA, Prasad A, Lennon RJ, Wright RS, Lerman A, Rihal CS: **Four-year recurrence rate and prognosis of the apical ballooning syndrome.** *J Am Coll Cardiol* 2007, **50**(5):448-452.
26. Singh K, Carson K, Usmani Z, Sawhney G, Shah R, Horowitz J: **Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy.** *Int J Cardiol* 2014, **174**(3):696-701.
27. Gianni M, Dentali F, Grandi AM, Sumner G, Hiralal R, Lonn E: **Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review.** *Eur Heart J* 2006, **27**(13):1523-1529.
28. El-Battrawy I, Santoro F, Stiermaier T, Moller C, Guastafierro F, Novo G, Novo S, Mariano E, Romeo F, Romeo F *et al*: **Incidence and Clinical Impact of Recurrent Takotsubo Syndrome: Results From the GEIST Registry.** *J Am Heart Assoc* 2019, **8**(9):e010753.
29. Cammann VL, Sarcon A, Ding KJ, Seifert B, Kato K, Di Vece D, Szawan KA, Gili S, Jurisic S, Bacchi B *et al*: **Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry.** *J Am Heart Assoc* 2019, **8**(15):e010881.

30. Desai A, Noor A, Joshi S, Kim AS: **Takotsubo cardiomyopathy in cancer patients.** *Cardiooncology* 2019, **5**:7.
31. Tornvall P, Collste O, Ehrenborg E, Jarnbert-Petterson H: **A Case-Control Study of Risk Markers and Mortality in Takotsubo Stress Cardiomyopathy.** *J Am Coll Cardiol* 2016, **67**(16):1931-1936.
32. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM: **Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.** *CA Cancer J Clin* 2016, **66**(4):309-325.
33. Ewer MS, Ewer SM: **Cardiotoxicity of anticancer treatments.** *Nat Rev Cardiol* 2015, **12**(11):620.
34. Desai R, Abbas SA, Goyal H, Durairaj A, Fong HK, Hung O, Sachdeva R, Barac A, Yusuf SW, Kumar G: **Frequency of Takotsubo Cardiomyopathy in Adult Patients Receiving Chemotherapy (from a 5-Year Nationwide Inpatient Study).** *Am J Cardiol* 2019, **123**(4):667-673.
35. Ederhy S, Cautela J, Ancedy Y, Escudier M, Thuny F, Cohen A: **Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors.** *JACC Cardiovasc Imaging* 2018, **11**(8):1187-1190.
36. Anderson RD, Brooks M: **Apical takotsubo syndrome in a patient with metastatic breast carcinoma on novel immunotherapy.** *Int J Cardiol* 2016, **222**:760-761.
37. Joy PS, Guddati AK, Shapira I: **Outcomes of Takotsubo cardiomyopathy in hospitalized cancer patients.** *J Cancer Res Clin Oncol* 2018, **144**(8):1539-1545.
38. Dharmarajan K, Wang Y, Lin Z, Normand ST, Ross JS, Horwitz LI, Desai NR, Suter LG, Drye EE, Bernheim SM *et al*: **Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge.** *JAMA* 2017, **318**(3):270-278.

Tables

Table 1.

Baseline characteristics of Takotsubo Syndrome Patients with or without Malignancy

Characteristics				
	All	Malignancy	No Malignancy	P Value
Number of admissions	61583	7542 (12.2)*	54041 (87.8)	
Patient characteristics				
Age, mean (SE), y	66.7 (0.1)	70.6 (0.2)	66.1 (0.1)	<0.001†
Age≥70 yrs	27109 (44.0)	4328 (57.4)	22781 (42.2)	<0.001‡
Female	54708 (88.8)	6499 (86.2)	48209 (89.2)	<0.001
Smoking history	21834 (35.5)	2864 (38.0)	18970 (35.1)	0.005
Hypertension	40597 (65.9)	4900 (65.0)	35697 (66.1)	0.350
Diabetes mellitus	11701 (19.0)	1405 (18.6)	10296 (19.1)	0.620
Dyslipidemia	26830 (43.6)	3102 (41.1)	23728 (43.9)	0.014
Known coronary artery disease	25910 (42.1)	3495 (46.3)	22415 (41.5)	<0.001
Previous myocardial infarction	3833 (6.2)	444 (5.9)	3389 (6.3)	0.463
Previous PCI	2988 (4.9)	341 (4.5)	2647 (4.9)	0.458
Previous CABG	933 (1.5)	91 (1.2)	842 (1.6)	0.177
Family history of coronary artery disease	5249 (8.5)	448 (5.9)	4801 (8.9)	<0.001
Congestive heart failure	18531 (30.1)	2552 (33.8)	15979 (29.6)	<0.001
Peripheral vascular disease	4544 (7.4)	608 (8.1)	3936 (7.3)	0.156
Chronic pulmonary disease	17732 (28.8)	2396 (31.8)	15336 (28.4)	<0.001
Chronic kidney disease	4862 (7.9)	670 (8.9)	4192 (7.8)	0.075
Liver disease	1238 (2.0)	116 (1.5)	1122 (2.1)	0.070
Anemia	9425 (15.3)	1456 (19.3)	7969 (14.7)	<0.001
Atrial fibrillation	8744 (14.2)	1338 (17.7)	7406 (13.7)	<0.001

Coagulopathy	2699 (4.4)	485 (6.4)	2214 (4.1)	<0.001
Collagen vascular disease	2683 (4.4)	282 (3.7)	2401 (4.4)	0.117
Fluid/electrolyte disorders	18576 (30.2)	2658 (35.2)	15918 (29.5)	<0.001
Obesity	6554 (10.6)	537 (7.1)	6017 (11.1)	<0.001
Other neurological disorders	5196 (8.4)	599 (7.9)	4597 (8.5)	0.429
Pulmonary circulatory disease	1243 (2.0)	252 (3.3)	991 (1.8)	<0.001
Valvular heart disease	1592 (2.6)	296 (3.9)	1296 (2.4)	<0.001
Median household income				<0.001
First quartile	16024 (26.4)	1739 (23.3)	14285 (26.8)	
Second quartile	15865 (26.1)	1957 (26.2)	13908 (26.1)	
Third quartile	14949 (24.6)	1816 (24.3)	13133 (24.7)	
Fourth quartile	13849 (22.8)	1953 (26.2)	11896 (22.4)	
Primary payer				<0.001
Medicare	37851 (61.5)	5462 (72.4)	32389 (59.9)	
Medicaid	4028 (6.5)	389 (5.2)	3639 (6.7)	
Private including HMO	15388 (25.0)	1435 (19.0)	13953 (25.8)	
Self-pay/no charge/other	4315 (7.0)	256 (3.4)	4059 (7.5)	
Hospital characteristics				
Hospital teaching status				<0.001
Teaching	35931 (58.3)	4799 (63.6)	31132 (57.6)	
Nonteaching	25652 (41.7)	2743 (36.4)	22909 (42.4)	
Hospital location				0.149
Rural	212 (0.3)	13 (0.2)	199 (0.4)	
Urban	61371 (99.7)	7529 (99.8)	53842 (99.6)	
Hospital bed size				0.240

Small	4612 (7.5)	503 (6.7)	4109 (7.6)	
Medium	13769 (22.4)	1643 (21.8)	12126 (22.4)	
Large	43203 (70.2)	5396 (71.5)	37807 (70.0)	
Length of stay >5 days	18588 (30.2)	3134 (41.6)	15454 (28.6)	<0.001
Disposition				<0.001
Home	44092 (71.6)	4552 (60.4)	39540 (73.2)	
Facility[§]	15710 (25.5)	2632 (34.9)	13078 (24.2)	
AMA/unknown	1777 (2.9)	358 (4.7)	1419 (2.6)	
Mood disorders	11502 (18.7)	11354 (18.0)	10148 (18.8)	0.378
Substance abuse	2676 (4.3)	165 (2.2)	2511 (4.6)	<0.001
Delirium/Dementia	2667 (4.3)	365 (4.8)	2302 (4.3)	0.213
Personality disorder	103 (0.2)	0 (0)	103 (0.2)	0.061
Acute decompensated heart failure	10571 (17.2)	1472 (19.5)	9099 (16.8)	0.003
Cardiogenic shock	3564 (5.8)	582 (7.7)	2982 (5.5)	<0.001
Cardiac arrest	1663 (2.7)	221 (2.9)	1442 (2.7)	0.544
Postop stroke (complication)	792 (1.3)	103 (1.4)	689 (1.3)	0.704
Arrhythmia	16868 (27.4)	2394 (31.7)	14474 (26.8)	<0.001

Abbreviations: SE, standard error; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; HMO, health maintenance organization; AMA, against medical advice.

*Values are presented as number (percentage) of patients unless otherwise indicated.

†Survey-specific linear regression was performed.

‡Rao-Scott χ^2 test was used for all statistical tests unless stated otherwise.

§Facility includes skilled nursing facility, intermediate care facility, and inpatient rehabilitation facility.

Table 2.

In-hospital and 30-day Outcomes of Takotsubo Syndrome Stratified by Presence of Malignancy

Outcomes	N (%)	Unadjusted		Adjusted*	
		OR (95% CI)	P Value	OR (95% CI)	P Value
Number of patients	7542 (12.2)				
Inhospital mortality					
Overall	1472 (2.4)				
No malignancy	1161 (2.1)	1 (Ref)		1(Ref)	
Malignancy	311 (4.1)	1.96 (1.56-2.46)	<0.001	1.68 (1.29-2.17)	<0.001
30-day readmission mortality					
Overall	254 (0.4)				
No malignancy	205 (0.4)	1(Ref)			
Malignancy	49 (0.6)	1.73 (0.88-3.42)	0.114	-	
30-day total mortality†					
Overall	1726 (2.8)				
No malignancy	1366 (2.5)	1(Ref)		1(Ref)	
Malignancy	360 (4.8)	1.96 (1.56-2.46)	<0.001	1.62 (1.25-2.10)	<0.001
30-day readmission					
Overall	7173 (11.6)				
No malignancy	5971 (11.0)	1(Ref)		1(Ref)	
Malignancy	1202 (15.9)	1.53 (1.34-1.75)	<0.001	1.33 (1.15-1.53)	<0.001

Abbreviations: OR, odds ratio; CI, confidence interval; Ref, reference.

* Survey-specific multivariate generalized linear model was created with each outcome including all predictors with p values < 0.1 in the univariate analysis. Covariates for inhospital mortality and 30-day total mortality are available in the Supplementary Table I and II.

†Thirty-day total mortality included inhospital mortality and 30-day readmission mortality together.

Table 3.

Independent Predictors of 30-Day Readmission After Index Hospitalization With Takotsubo Syndrome

Variables	Unadjusted OR	Lower CI	Higher CI	P value	Adjusted OR*	Lower CI	Higher CI	P value
Malignancy	1.53	1.34	1.75	<0.001	1.33	1.15	1.53	<0.001
Length of stay >5 days	2.45	2.23	2.69	<0.001	1.48	1.31	1.68	<0.001
Age≥70 yrs	1.34	1.22	1.46	<0.001	0.95	0.84	1.07	0.378
Diabetes mellitus	1.27	1.13	1.42	<0.001	1.14	1.01	1.28	0.035
Family hx of CAD	0.56	0.46	0.69	<0.001	0.78	0.63	0.97	0.024
Chronic pulmonary disease	1.69	1.54	1.86	<0.001	1.40	1.27	1.55	<0.001
Chronic Kidney disease	1.88	1.64	2.16	<0.001	1.36	1.17	1.59	<0.001
Anemia	1.90	1.70	2.12	<0.001	1.26	1.12	1.42	<0.001
Atrial fibrillation	1.61	1.43	1.81	<0.001	1.24	1.08	1.41	0.002
Fluid and electrolyte disturbance	1.75	1.58	1.92	<0.001	1.20	1.07	1.34	0.001
Median household income (Ref: 1 st quartile)								
Second quartile	0.92	0.80	1.04	0.188	0.97	0.85	1.11	0.689
Third quartile	0.83	0.72	0.94	0.004	0.90	0.79	1.03	0.10
Fourth quartile	0.75	0.66	0.85	<0.001	0.85	0.74	0.97	0.01
Primary payer (Ref: Medicare)								
Medicaid	1.11	0.93	1.31	0.250	1.25	1.02	1.53	0.032
Private including HMO	0.53	0.46	0.60	<0.001	0.75	0.64	0.88	<0.001
Self-pay/no charge/other	0.61	0.50	0.74	<0.001	0.82	0.66	1.00	0.054
Disposition								

(Ref: Home)								
Facility	2.60	2.35	2.87	<0.001	1.65	1.46	1.87	<0.001
AMA/unknown	0.37	0.22	0.62	<0.001	0.25	0.15	0.41	<0.001

Abbreviations: OR, odds ratio; CI, confidence interval; CAD, coronary artery disease; HMO, health maintenance organization; AMA, against medical advice.

* Survey-specific multivariate generalized linear model was created with an outcome of 30-day readmission including all predictors with p values < 0.1 in the univariate analysis. Covariates for in-hospital mortality and 30-day total mortality are available in the Supplementary Table I and II.

Table 4.
Independent Predictors of Higher 30-Day Total Cost of Hospitalization in Patients with TTS

Variables	Unadjusted				Adjusted			
	Beta	Lower CI	Higher CI	P value	Beta	Lower CI	Higher CI	P value
Malignancy	0.093	0.078	0.108	<0.001	0.013	0.005	0.022	0.003
30-day readmission	0.327	0.312	0.341	<0.001	0.223	0.212	0.234	<0.001
Length of stay >5 days	0.459	0.449	0.469	<0.001	0.31	0.301	0.318	<0.001
Age≥70 yrs	0.033	0.023	0.042	<0.001	-0.026	-0.033	-0.018	<0.001
Female (Ref: male)	-0.109	-0.130	-0.089	<0.001	-0.048	-0.061	-0.036	<0.001
Diabetes mellitus	0.041	0.029	0.052	<0.001	0.015	0.007	0.022	<0.001
Dyslipidemia	-0.070	-0.080	-0.061	<0.001	-0.014	-0.02	-0.008	<0.001
Previous PCI	-0.024	-0.043	-0.005	0.015	-0.02	-0.034	-0.006	0.005
Family history of CAD	-0.125	-0.138	-0.112	<0.001	-0.013	-0.024	-0.003	0.009
Congestive heart failure	0.184	0.173	0.194	<0.001	0.027	0.019	0.034	<0.001
Peripheral vascular disease	0.121	0.102	0.139	<0.001	0.028	0.016	0.04	<0.001
Chronic pulmonary disease	0.107	0.096	0.118	<0.001	0.019	0.012	0.026	<0.001
Chronic kidney disease	0.169	0.150	0.188	<0.001	0.03	0.017	0.044	<0.001
Chronic liver disease	0.200	0.157	0.242	<0.001	0.04	0.012	0.068	0.005
Anemia	0.217	0.203	0.231	<0.001	0.031	0.022	0.041	<0.001
Atrial fibrillation	0.140	0.124	0.156	<0.001	0.018	0.008	0.028	<0.001
Coagulopathy	0.339	0.309	0.368	<0.001	0.097	0.078	0.115	<0.001
Drug abuse	0.114	0.089	0.140	<0.001	0.027	0.01	0.043	0.001
Fluid/electrolyte disorders	0.257	0.246	0.269	<0.001	0.059	0.051	0.068	<0.001

Other neurological disorders	0.132	0.112	0.152	<0.001	0.027	0.014	0.04	<0.001
Pulmonary circulatory disease	0.407	0.369	0.444	<0.001	0.096	0.065	0.127	<0.001
Valvular heart disease	0.323	0.293	0.353	<0.001	0.06	0.038	0.083	<0.001
Cardiogenic shock	0.418	0.396	0.440	<0.001	0.122	0.102	0.142	<0.001
Cardiac arrest	0.403	0.372	0.434	<0.001	0.147	0.122	0.173	<0.001
Intraaortic balloon pump	0.415	0.383	0.448	<0.001	0.086	0.058	0.114	<0.001
Median household income (Ref: first quartile)								
Second quartile	0.007	-0.008	0.023	0.339	0.027	0.018	0.036	<0.001
Third quartile	0.025	0.010	0.040	0.001	0.051	0.042	0.061	<0.001
Fourth quartile	0.037	0.022	0.053	<0.001	0.077	0.067	0.088	<0.001
Primary payer (Ref: medicare)								
Medicaid	0.041	0.020	0.062	<0.001	0.033	0.019	0.047	<0.001
Private	-0.083	-0.094	-0.072	<0.001	-0.003	-0.011	0.006	0.506
Self-pay / no charge / others	-0.069	-0.087	-0.050	<0.001	-0.001	-0.014	0.012	0.897
Disposition (Ref: home)								
Facility	0.316	0.304	0.327	<0.001	0.077	0.069	0.086	<0.001
AMA/unknown	0.346	0.311	0.380	<0.001	0.116	0.091	0.141	<0.001
Year (per year)	0.009	0.004	0.014	<0.001	0.006	-0.000	0.011	0.060

Abbreviations: TTS, Takotsubo syndrome; PCI, percutaneous coronary intervention; CAD, coronary artery disease.

*Survey-specific multivariate linear regression model was created with an outcome of log-transformed cumulative cost including all predictors with p values < 0.1 in the univariate analysis. Hospital ID was also

included as a covariable for consideration of hospital fixed-year effect (insignificant contribution, not shown).

Figures

Figure 1

Cumulative Rates of 30-day Readmissions according to the Presence of Malignancy. Data show unadjusted 30-day readmission rate in TTS patients with malignancy (red) and in those without malignancy (blue). Abbreviations: TTS, Takotsubo syndrome.

Figure 2

Timing and Causes of 30-day Readmissions for Takotsubo Syndrome with or without Malignancy. (A) Time to readmission in TTS patients with malignancy. (B) Time to readmission in TTS patients without malignancy. (C) Histograms representing different causes of 30-day readmissions in TTS patients with malignancy and without malignancy. Abbreviations: TTS, Takotsubo syndrome.

Figure 3

Thirty-day Readmission Rates of Takotsubo Syndrome by Cancer Types. (A) Prevalence of each type of cancer in TTS patients with malignancy. (B) 30-day readmission rates according to the cancer type in TTS patients with malignancy. Abbreviations: TTS, Takotsubo syndrome.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [NRDTakotsuboSupplement.docx](#)